Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA Close To Deal With Tauzin; Changes In Reg Affairs, PR Line Up

Executive Summary

The Pharmaceutical Research & Manufacturers of America is understood to be close to finalizing an agreement with Rep. Billy Tauzin (R-La.) to take over as the new CEO of the trade group

You may also be interested in...



PhRMA Readies “Access & Affordability” Campaign; PR Overhaul Complete

The Pharmaceutical Research & Manufacturers of America is establishing an internal group on drug access and affordability in preparation for launching a nationwide public educational effort on the theme

PhRMA Readies “Access & Affordability” Campaign; PR Overhaul Complete

The Pharmaceutical Research & Manufacturers of America is establishing an internal group on drug access and affordability in preparation for launching a nationwide public educational effort on the theme

PhRMA CEO Tauzin Takes Over Jan. 3: PR Focus Begins At The Top

PhRMA's new management team under CEO Billy Tauzin will place a high priority on communications and partnerships with other stakeholders in healthcare policy debates

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043360

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel